Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic m6A MeRIP-seq in human metastatic ovarian carcinoma and in situ ovarian carcinoma tissue

ABSTRACT: Transcriptomic m6A MeRIP-seq in human metastatic ovarian carcinoma and in situ ovarian carcinoma tissue

PROVIDER: PRJNA858027 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR20097077_1.fastq.gz	Fastqsanger.gz
	SRR20097077_2.fastq.gz	Fastqsanger.gz
	SRR20097078_1.fastq.gz	Fastqsanger.gz
	SRR20097078_2.fastq.gz	Fastqsanger.gz
	SRR20097079_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 24

Similar Datasets

Transcriptomic m6A MeRIP-seq in human metastatic ovarian carcinoma and in situ ovarian carcinoma tissue

Project description:To investigate the mRNA m6A modification profiling in human metastatic ovarian carcinoma and in situ ovarian carcinoma tissue, we performed m6A MeRIP-seq(GenSeq®️ m6A MeRIP Kit) with the total RNA extacted from these tissue samples.

2022-07-15 | GSE208023 | GEO

m6A meRIP-Seq from Ythdf2CTL pre-leukemic cells

Project description:The mRNA m6A reader YTHDF2 is overexpressed in a broad spectrum of human acute myeloid leukemias (AML). To understand the role of YTHDF2 in AML, we generated m6A meRIP-seq libraries form Ythdf2fl/fl (Ythdf2CTL) pre-leukemic cells.

2019-04-05 | E-MTAB-6791 | biostudies-arrayexpress

m6A meRIP-Seq from Ythdf2CKO pre-leukemic cells

2019-04-05 | E-MTAB-7783 | biostudies-arrayexpress

m6A-meRIP sequencing

Project description:m6A-meRIP sequencing

| PRJNA719306 | ENA

Comprehensive role of Zfp217 in m6A methylation [MeRIP-seq]

Project description:Many transcriptional and epigenetic networks must be integrated to maintain self-renewal and pluripotency in embryonic stem cells (ESCs) and to enable induced pluripotent stem cell (iPSC) reprogramming. Here, we explore the role of Zfp217 as a key transcriptional factor in maintaining ES cell self-renewal by performing meRIP analysis in control and Zfp217-depleted mouse stem cells. Examination of m6A levels from total RNA in control and Zfp217 shRNA infected mouse stem cells

2015-10-30 | E-GEOD-65734 | biostudies-arrayexpress

Transcriptome-wide m6A methylome of endometrioid ovarian cancer and ovarian endometriosis

Project description:Emerging studies have revealed that N6-methyladenosine modification is involved in the development of various cancers. However, the m6A modification pattern of endometrioid ovarian cancer (EOC) has not been demonstrated. In the present study, high-throughput sequencing combined with methylated RNA immunoprecipitation (MeRIP-seq) and RNA sequencing were used to obtain the transcriptome-wide m6A modifications of endometrioid ovarian cancer for the first time.

2022-02-18 | GSE196748 | GEO

The proteome of clear cell ovarian carcinoma

Project description:Clear cell ovarian carcinoma (CCOC) is the second most common subtype of epithelial ovarian carcinoma. Late stage CCOC is not responsive to gold-standard chemotherapy and result in suboptimal outcome for patients. In-depth molecular insight is urgently needed to stratify the disease and drive therapeutic development. We conducted global proteomics in 192 cases of CCOC comparing to other epithelial ovarian carcinoma subtypes.

2022-09-02 | PXD032355 | Pride

Role of FTO in ovarian cancer (MeRIP-Seq)

Project description:Role of FTO in ovarian cancer (MeRIP-Seq)

| PRJNA538931 | ENA

Spatially resolved transcriptomics of high-grade serous ovarian carcinoma

Project description:Bulk and single-cell RNA sequencing do not provide full characterization of tissue spatial diversity in cancer samples, and currently available in situ techniques (multiplex immunohistochemistry, imaging mass cytometry) allow for only limited analysis of a small number of targets. The current study represents the first comprehensive approach to spatial transcriptomics of high-grade serous ovarian carcinoma using intact tumor tissue. We selected a small cohort of patients with highly annotated high-grade serous ovarian carcinoma, categorized them by response to neoadjuvant chemotherapy (poor or excellent), and analyzed pre-treatment tumor tissue specimens. Our study uncovered extensive differences in tumor composition between the poor responders and excellent responders to chemotherapy, related to cell cluster organization and localization. This in-depth characterization of high-grade serous ovarian carcinoma tumor tissue from poor and excellent responders showed that spatial interactions between cell clusters may influence chemo-responsiveness more than cluster composition alone.

2021-12-02 | GSE189843 | GEO

The immunopeptidomic landscape of ovarian carcinoma

Project description:Immunopeptidome analysis of ovarian carcinoma tissues was performed to characterize the HLA class I and class II presented ligandome of this malignancy.

2017-11-02 | PXD007635 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data